Ownership
Private
Employees
~50
Therapeutic Areas
OncologyImmunology
Stage
Phase 1
Modalities
Liquid biopsy

Aqtual General Information

Enrolled first patient in PRIMA-102 trial to evaluate technology for selecting effective treatments in rheumatoid arthritis patients. Platform analyzes previously unexplored cell-free DNA fragments for protein regulation, epigenetics, and transcriptomics.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Hayward, California
United States

Drug Pipeline

Cell-free DNA diagnostic test
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Aqtual's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Aqtual Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Aqtual's complete valuation and funding history, request access »

Aqtual Investors

Genoa Ventures
Investor Type: Venture Capital
Holding: Minority
Manta Ray Ventures
Investor Type: Venture Capital
Holding: Minority
Yu Galaxy
Investor Type: Venture Capital
Holding: Minority